The Oxford Vaccine Group, led by Prof Andrew Pollard, is renowned for collaborating with Oxford’s Jenner Institute in developing the R21 vaccine – a groundbreaking malaria jab rolled out across Africa last year that is expected to reduce malaria deaths by at least 30 per cent.
Led by the Oxford Vaccine Group at the University of Oxford, the phase I trial – funded by USAID – was testing two innovative vaccines designed to prevent the malaria parasite from entering the bloodstream.
Cutting edge Oxford malaria vaccine trial in jeopardy as USAID payments frozen Dozens of UK volunteers left in limbo by Trump cuts after taking the experimental drug in bid to help science.
Unlike the existing malaria vaccines, which aim to stop the malaria parasite from multiplying in the liver, the new jabs are designed to stop the vaccine getting into the blood in the first place.
Scientists at Oxford lead the world in malaria vaccine research and last year teamed up with the Serum Institute in India to release a ground-breaking jab now being rolled out across large parts of Africa.
